ThioPharma

ThioPharma is a preclinical-stage biotechnology company focused on revolutionizing drug delivery through its proprietary Thiol-Mediated Uptake (TMU) platform. Co-founded by renowned scientists from Stanford University and the University of Geneva, the company develops cell-penetrating poly(disulfide)s (CPDs) that facilitate the efficient entry of diverse therapeutic payloads—including oligonucleotides, peptides, and small molecules—into target cells. By leveraging the unique chemistry of sulfur and thiol-disulfide exchange, ThioPharma aims to overcome traditional barriers to intracellular delivery, potentially enhancing the efficacy and safety of treatments for oncology, immunology, and genetic disorders. The company's technology represents a novel approach to unlocking the intracellular space for previously undruggable or poorly delivered therapeutic classes.